Compare Akamai Technologies, Inc. (AKAM) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Akamai Technologies, Inc. vs Heron Therapeutics Inc — how do they compare? Akamai Technologies, Inc. trades at $123.75 (market cap $16.77B), while Heron Therapeutics Inc trades at $0.35 (market cap $61.47M). The key difference: Akamai Technologies, Inc. is far larger — about 272.8× Heron Therapeutics Inc's market cap, and Akamai Technologies, Inc. is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| AKAM | HRTX | |
|---|---|---|
Market Cap | $16.77B | $61.47M |
Sector | Technology | Health |
52-Week High | $161.14 | $1.49 |
52-Week Low | $71.97 | $0.32 |
Enterprise Value | $22.75B | $168.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Akamai Technologies (AKAM) trades at $117.65, up 6.43% on the day, buoyed by a recent analyst upgrade. The stock shows bearish technical signals but has beaten earnings estimates for three consecutive quarters, with Q2 2026 revenue growth of 5% year-over-year. Profit margins are under pressure due to increased infrastructure investments, though cloud and security demand remains strong.
The outlook is mixed: solid revenue growth and a consensus price target of $150.11 suggest upside, but margin compression and bearish technicals pose risks. Investors should weigh the company's strategic positioning in AI and cybersecurity against profitability challenges and market volatility.
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Akamai Technologies, Inc.
Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.
Read more on AKAM →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
